Triple intraventricular chemotherapy for treatment of relapsed choroid plexus carcinoma

2021 ◽  
Author(s):  
Grace Lau ◽  
Julie Drummond ◽  
Nataliya Zhukova ◽  
Lisa Janson
Keyword(s):  
Choroid Plexus ◽  
Choroid Plexus Carcinoma ◽  
Intraventricular Chemotherapy

scholarly journals DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii287-iii287
Author(s):  
Grace Lau ◽  
Lisa Janson ◽  
Julie Drummond ◽  
Nataliya Zhukova
Keyword(s):  
Choroid Plexus ◽  
Case Reports ◽  
Palliative Radiotherapy ◽  
Previous Treatment ◽  
Choroid Plexus Carcinoma ◽  
Temporal Region ◽  
Craniospinal Radiation ◽  
Intraventricular Chemotherapy ◽  
One Year ◽  
Relapsed Disease

Abstract Limited evidence for the optimal management of relapsed choroid plexus carcinoma (CPC) exists, with a few case reports involving surgery, radiotherapy and intravenous chemotherapy. However, the safety and tolerability of intraventricular chemotherapy in this setting has not been widely studied. We describe a case where triple intraventricular chemotherapy was administered to a child with relapsed metastatic CPC. A 7-year-old male with a history of CPC presented with relapsed metastatic disease. At initial diagnosis at 4 years of age, treatment involved gross total resection of an intraventricular mass in the left temporal region followed by chemotherapy and autologous stem cell transplantation (SCT) according to HEADSTART II-D. One year after SCT, craniospinal radiation was delivered following radiological relapse, achieving a partial response. Given previous treatment-limiting myelosuppression, intraventricular chemotherapy via Ommaya® reservoir with thiotepa 5mg, etoposide 0.5mg and topotecan 0.4mg twice a week (non-weight-based dosing) was commenced taking into consideration pharmaceutical formulation aspects for optimal intraventricular drug delivery. After six cycles of intraventricular chemotherapy, palliative radiotherapy was administered due to radiological progression. Following completion, weekly triple intraventricular chemotherapy continued for 9 months. The patient remained out of hospital with the main side effects being fatigue and occasional nausea amenable to ondansetron. This case study demonstrates the safety and tolerability of a triple intraventricular chemotherapy regimen used to delay disease progression and prolong quality of life in a child with relapsed CPC in the palliative setting. This could provide an alternative treatment regimen for patients with relapsed disease.

scholarly journals ATRT-04. INHERITED RHABDOID PREDISPOSITION SYNDROME: A CASE OF CHOROID PLEXUS CARCINOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN SIBLINGS

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii276-iii276
Author(s):  
Alexis Judd ◽  
Erin Wright ◽  
Sarah Rush
Keyword(s):  
Overall Survival ◽  
Choroid Plexus ◽  
Disease Recurrence ◽  
Genetic Alterations ◽  
Rhabdoid Tumor ◽  
Choroid Plexus Carcinoma ◽  
High Dose ◽  
Atypical Teratoid Rhabdoid Tumor ◽  
Increased Risk ◽  
Atypical Teratoid

Abstract Choroid plexus carcinoma (CPC) and Atypical teratoid/rhabdoid tumor (ATRT) are aggressive, malignant brain cancers most commonly arising in children less than 3 years of age. These tumors often have genetic alterations in the tumor suppressor gene SMARCB1/INI1. Rhabdoid predisposition syndrome (RTPS) categorizes patients with germline mutations in SMARCB1 or SMARCA4, leading to a markedly increased risk of developing rhabdoid tumors. Both CPC and ATRT have been demonstrated in patients with these rhabdoid predisposition syndromes. In general, these tumors tend to have a poor prognosis. However, with the presence of a SMARCB1 mutation they may have improved overall survival. We present two interesting cases of siblings with maternally inherited SMARCB1 mutations: one a 21-month-old male who presented with an ATRT and another a 10 month old female who presented with a CPC. The ATRT was treated as per the Children’s Oncology Group study ACNS0333 with high dose chemotherapy and stem cell rescue as well as cranial radiation. The CPC was treated as per CPT-SIOP 2009 with etoposide, cyclophosphamide and vincristine. Unlike other patients with these aggressive tumors, both of these patients are alive without evidence of disease recurrence 8 and 7 years post therapy, respectively. Additional genomic testing on both tumors is currently pending in order to potentially identify other mutations that may impact survival. These cases further illustrate the similar profile of two very different tumors with improved overall survival that may be secondary to mutations in SMARCB1 in RTPS.

P0261 CHOROID PLEXUS CARCINOMA – A CLINICAL CASE

2009 ◽  
Vol 20 ◽  
pp. S92
Author(s):  
Pedro Figueiredo ◽  
Corinna Lohmann ◽  
Henrique Santos
Keyword(s):  
Choroid Plexus ◽  
Clinical Case ◽  
Choroid Plexus Carcinoma

scholarly journals Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma

2017 ◽  
Vol 39 (8) ◽  
pp. e473-e475 ◽  
Author(s):  
Matthew McEvoy ◽  
Nathan Robison ◽  
Peter Manley ◽  
Torunn Yock ◽  
Kristine Konopka ◽  
...  
Keyword(s):  
Choroid Plexus ◽  
Successful Treatment ◽  
Choroid Plexus Carcinoma ◽  
Li Fraumeni Syndrome ◽  
Li Fraumeni

scholarly journals INI1 Protein Expression Distinguishes Atypical Teratoid/Rhabdoid Tumor from Choroid Plexus Carcinoma

2005 ◽  
Vol 64 (5) ◽  
pp. 391-397 ◽  
Author(s):  
Alexander R. Judkins ◽  
Peter C. Burger ◽  
Ronald L. Hamilton ◽  
Bette Kleinschmidt-DeMasters ◽  
Arie Perry ◽  
...  
Keyword(s):  
Protein Expression ◽  
Choroid Plexus ◽  
Rhabdoid Tumor ◽  
Choroid Plexus Carcinoma ◽  
Atypical Teratoid Rhabdoid Tumor ◽  
Atypical Teratoid

ACUTE LYMPHOBLASTIC LEUKEMIA COMPLICATED BY CHOROID PLEXUS CARCINOMA

1999 ◽  
Vol 16 (1) ◽  
pp. 75-77 ◽  
Author(s):  
Charles T. Quinn ◽  
Barton A. Kamen,
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Choroid Plexus ◽  
Lymphoblastic Leukemia ◽  
Choroid Plexus Carcinoma

Pigmented choroid plexus carcinoma: A cytogenetic and ultrastructural study

1997 ◽  
Vol 96 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Sheila M. Dobin ◽  
Ludvik R. Donner
Keyword(s):  
Choroid Plexus ◽  
Ultrastructural Study ◽  
Choroid Plexus Carcinoma

scholarly journals Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma

2012 ◽  
Vol 2 (2) ◽  
pp. 49 ◽  
Author(s):  
Chihiro Kawakami ◽  
Akiko Inoue ◽  
Kimitaka Takitani ◽  
Motomu Tsuji ◽  
Kimiko Wakai ◽  
...  
Keyword(s):  
Growth Factor ◽  
Choroid Plexus ◽  
Standard Dose ◽  
Growth Factor Receptor ◽  
Female Child ◽  
Disease Recurrence ◽  
Choroid Plexus Carcinoma ◽  
High Dose ◽  
Imatinib Treatment ◽  
Stem Cell Rescue

We herein report a female child with choroid plexus carcinoma treated with standard dose of imatinib at disease recurrence. This patient failed initial twice-surgical resections, central nervous system (CNS) irradiation, and adjuvant chemotherapies and high-dose thiotepa and melphalan with auto peripheral blood stem cell rescue. Finally, imatinib treatment was undergone as a palliative setting, however the tumor did not reduce and the patient died of tumor bleedings. We consider that the reasons for the failure are as follows: i) adequate CNS level of imatinib were not obtained because of the blood brain barrier, ii) the lack of plateletderived growth factor receptor beta expression in our case may have a crucial role.

scholarly journals Choroid Plexus Carcinoma: A Rare Tumor in Adult

2014 ◽  
Vol 05 (04) ◽  
pp. 146-149 ◽  
Author(s):  
Chi-Man Yip ◽  
Hui-Hwa Tseng ◽  
Shu-Shong Shu-Shong Hsu
Keyword(s):  
Choroid Plexus ◽  
Choroid Plexus Carcinoma ◽  
Rare Tumor
Sign in / Sign up

Export Citation Format

Share Document